Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.
Robin Foà, MD, leads a discussion on the primary takeaways from the GIMEMA LAL2116, D-ALBA trial, particularly the prognostic impact of the IKZF1-plus genotype and the Ikaros mutation.
Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.
Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.
Researchers of Sanford Burnham Prebys Medical Discovery Institute indicates that p62 may represent a link connecting obesity, inflammation, and progression of certain cancers.
Jorge E. Cortes, MD, shares his experience with tyrosine kinase inhibitors as treatment of patients with chronic myeloid leukemia.
José Baselga, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses biomarker research for patients with breast cancer.
Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses combination regimens that seem promising and are under investigation in the treatment landscape of chronic lymphocytic leukemia.
Jose Pacheco, MD, discusses the mechanism of action of trastuzumab deruxtecan in patients with HER2-overexpressing metastatic non–small cell lung cancer.
Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a study that examined the molecular profile of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC) stratified by smoking status.
Drs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.
Josep Llovet, MD, discusses the effiacy of TACE treatment with or without lenvatinib plus pembrolizumab in intermediate-stage hepatocellular carcinoma.
Josep Tabernero, MD, PhD, discusses findings from the phase 3 SUNLIGHT trial investigating the combination of bevacizumab plus trifluridine/tipiracil vs TAS-102 alone in patients with refractory metastatic colorectal cancer.
Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the role of surgery in head and neck cancer.
Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, professor of Medicine & Obstetrics, Gynecology, and Women’s Health at the Albert Einstein College of Medicine, and associate chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, discusses the utility of liquid biopsies in breast cancer.
Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.
In July, UnitedHealthcare (UHC) reported that an innovative program using bundled payment for cancer care resulted in an impressive 34% reduction in medical costs when compared with costs for a control group
Joseph Chao, MD, discusses the utility of microsatellite instability (MSI) status as a prognostic biomarker in gastric and gastroesophageal cancer.
Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.
Joseph F. Renzulli, II, MD, FACS, assistant professor of surgery (urology) clinical, Alpert Medical School, discusses the expanded access program in the United States for radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.
Joseph G. Jurcic, MD, discusses the evolution of combination therapies in the management of myelofibrosis.
Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).
Joseph Leach, MD, medical oncologist at Minnesota Oncology, discusses the use of brigatinib (Alunbrig) in ALK-positive non–small cell lung cancer (NSCLC).